Exicure, Inc. earnings releases XCUR

Annual Quarterly

Exicure, Inc. last reported quarterly results on Nov 7, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $0 and diluted EPS of -$0.39. It usually reports 38–46 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 38–46 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Nov 7, 2025 38 days after quarter end	Q3 FY2025 ended Sep 30, 2025	0	-2 -123.4%	-0.39 +31.6%
Aug 8, 2025 39 days after quarter end	Q2 FY2025 ended Jun 30, 2025	0	-3 -336.8%	-0.41 -17.1%
Nov 14, 2024 45 days after quarter end	Q3 FY2024 ended Sep 30, 2024	0	-1 +79.2%	-0.57 +81.2%
May 16, 2024 46 days after quarter end	— ended Mar 31, 2024	—	—	—
Jul 14, 2023 14 days after quarter end	— ended Jun 30, 2023	—	—	—
Nov 14, 2022 45 days after quarter end	— ended Sep 30, 2022	—	—	—
Aug 15, 2022 46 days after quarter end	— ended Jun 30, 2022	—	—	—
May 16, 2022 46 days after quarter end	— ended Mar 31, 2022	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: XCUR (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Chicago, IL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1698530
Former names: Max-1 Acquisition Corp (until Sep 28, 2017)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.